• Hanmi Science unit Hanmi Pharm won South Korea MFDS marketing authorization for Epe auto-injector (efpeglenatide) obesity drug.
• Approval covers five strengths, positioning the GLP-1 therapy for chronic weight management in adults alongside diet and exercise.
• Authorization date: Oct. 7, 2026; filing date: Dec. 17, 2025.
• Launch preparations underway, targeting domestic supply before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007800680), on October 07, 2026, and is solely responsible for the information contained therein.